Cornerstone Therapeutics Divests Its Anti-Infective Assets

CARY, NC– – Cornerstone Therapeutics Inc. today announced the divestiture of certain product rights to Factive® tablets and the Spectracef® family of products in a series of transactions with Merus Labs …